For Treatment of Chronic Hepatitis B Virus Infection

Infectious Diseases
2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Brii Biosciences
Brii BiosciencesCA - San Mateo
1 program
1
BRII-179Phase 2
Vir Biotechnology
Vir BiotechnologyCA - San Francisco
1 program
1
BRII-179Phase 21 trial
Active Trials
NCT06491563Active Not RecruitingEst. Jun 2027

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
Vir BiotechnologyBRII-179

Clinical Trials (1)

Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)

Start: Aug 2024Est. completion: Jun 2027
Phase 2Active Not Recruiting

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space